Cutler Group’s Protagonist Therapeutics PTGX Stock Holding History

Cutler Group’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,600	Closed	-$8K	–	5884
2021 Q4	$8K	Buy	+1,600	New	+$50.6K	﹤0.01%	3880

Other funds holding PTGX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cutler Group's PTGX Position: Q2 2022 in Review

Cutler Group sold out of Protagonist Therapeutics (PTGX) in Q2 2022, closing a stake of 784 shares — an estimated $18K sold.

Cutler Group first reported a position in PTGX in Q3 2021 and held it in 3 quarters. The position peaked at $19K in Q4 2021. 130 funds tracked by Wall St. Rank hold PTGX as of Q2 2022.

Cutler Group reported no remaining Protagonist Therapeutics position as of Q2 2022 after selling out during the quarter.
Cutler Group sold 784 Protagonist Therapeutics shares in Q2 2022, an estimated $18K.
Cutler Group first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 3 quarters.
Cutler Group's Protagonist Therapeutics position peaked at $19K in Q4 2021.
130 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.